Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in a SARS-CoV-2 testing center on Reunion island
Authors: Joubert Antoine , Andry Fanny , Bertolotti Antoine , Accot Frédéric , Koumar Yatrika , Legrand Florian , Poubeau Patrice , Manaquin Rodolphe , Gérardin Patrick , Levin Cécile 
Published: October 2020

Background

As coronavirus 2019 (COVID-19) is spreading globally, several countries are handling dengue epidemics. As both infections are deemed to share similarities at presentation, it would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. Hence, we performed a retrospective cohort study to identify predictors of both infections.

Methodology/Principal Findings

All the subjects suspected of COVID-19 between March 23 and May 10, 2020, were screened for COVID-19 within the testing center of the University hospital of Saint-Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls. Adjusted Odds ratios (OR) and 95% Confidence Intervals (95%CI) were assessed. Over a two-month study period, we diagnosed 80 COVID-19, 60 non-severe dengue and 872 OFIs cases. Among these, we identified delayed presentation (>3 days) since symptom onset (Odds ratio 1.91, 95% confidence interval 1.07-3.39), contact with a COVID-19 positive case (OR 3.81, 95%CI 2.21-6.55) and anosmia (OR 7.80, 95%CI 4.20-14.49) as independent predictors of COVID-19, body ache (OR 6.17, 95%CI 2.69-14.14), headache (OR 5.03, 95%CI 1.88-13.44) and retro-orbital pain (OR 5.55, 95%CI 2.51-12.28) as independent predictors of dengue, while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.09-0.79) and upper respiratory tract infection symptoms were associated with OFIs.

Conclusions/Significance

Although prone to potential biases, these data suggest that non-severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue attack rates. At clinical presentation, eight basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.

Author Summary

As coronavirus 2019 (COVID-19) is spreading globally, several countries are facing dengue epidemics with the fear the two plagues might overburden their healthcare systems. On Reunion island, southwestern Indian ocean: dengue virus is circulating since 2004 under an endemo-epidemic pattern with yearly outbreaks peaking between March and May since 2015, whereas Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the pathogen responsible of COVID-19, emerged in March 2020, imported from the Bahamas. COVID-19 and dengue are deemed two clinically similar entities, especially within the first two days from symptom onset. In this context, we conducted a cohort study between March 23 and May 10, 2020, within a SARS-CoV-2 testing center, aimed at identifying the factors discriminating both infections. Surprisingly, we found that non-severe dengue was more symptomatic than mild to moderate COVID-19. Indeed, we found body ache, headache and retro-orbital pain to be indicative of dengue, whereas contact with a COVID-19 positive case, anosmia, delayed presentation (>3 days post symptom onset) and absence of active smoking were indicative of COVID-19. These findings highlight the need for accurate diagnostic tools and not to jeopardize dengue control in areas wherever COVID-19 dengue co-epidemics have the potential to wrought havoc to the healthcare system.